California COVID-19 Testing Task Force Update

May 20, 2020
Agenda

- Introductions and logistics
- Objectives
- Approach
- Progress
- Next steps
- Questions
Logistics

• **Participation by invitation only** – please send participation requests to testing.taskforce@state.ca.gov

• All of this is to facilitate a trusted, open dialogue in a highly fluid situation

• A newsletter will follow this meeting and can be used to share with/update others in your community
Today’s speakers

- **Dr. Charity Dean**, Assistant Director, California Department of Public Health
- **Paul Markovich**, President and CEO, Blue Shield of California
- **Dr. Christina Kong**, Vice Chair and Medical Director of Pathology & Clinical Lab, Stanford University

List of Task Force leaders provided on Task Force website at testing.covid19.ca.gov
Roles in this public-private partnership

• Appropriate state officials *always* make decisions

• Individuals from the private sector are providing important support at a critical juncture and *do not* make decisions
Two types of COVID-19 tests mentioned in these materials

<table>
<thead>
<tr>
<th>Detection of...</th>
<th>PCR (molecular diagnostic) and Antigen tests</th>
<th>Serological tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virus</td>
<td></td>
<td>Antibodies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Common sample type</th>
<th>PCR is gold standard for diagnostic testing</th>
<th>Do not diagnose infection, but can be useful for antibody detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nose nasal or throat swab</td>
<td>Blood/plasma</td>
<td></td>
</tr>
</tbody>
</table>

Key considerations

# Task Force goals and approach

## Our goals
- Increase total number of tests
- 24-hour turnaround
- 90% accuracy
- Equitable and convenient access

## Our approach

<table>
<thead>
<tr>
<th>Access</th>
<th>Establish statewide collection sites for equitable access</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test processing</td>
<td>Maximize throughput and turnaround time of labs</td>
</tr>
<tr>
<td>Statewide distribution</td>
<td>Establish a smart distribution of scarce supplies</td>
</tr>
<tr>
<td>Facilitate innovation</td>
<td>Provide recommendations on new, promising tests</td>
</tr>
<tr>
<td>Data and analytics</td>
<td>Track and report results</td>
</tr>
<tr>
<td>Community-driven workforce needs</td>
<td>Maximize using members of the community for the work</td>
</tr>
</tbody>
</table>
Reaching our goals will require taking a range of actions.

Current and expected number of COVID-19 tests in California
Tests/day (PCR Tests)

<table>
<thead>
<tr>
<th>Date</th>
<th>Tests/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>End of March (actual)</td>
<td>2,000</td>
</tr>
<tr>
<td>Goal by 4/17</td>
<td>10,000</td>
</tr>
<tr>
<td>Goal by 4/30</td>
<td>25,000</td>
</tr>
<tr>
<td>Goal by 5/31</td>
<td>60,000</td>
</tr>
</tbody>
</table>

Actions to increase test volumes:

- Increase capacity for existing labs to process tests
- Increase number of specimens collected for processing
- Assess and deploy new tests (e.g., point of care, serology)
Task Force is optimizing end-to-end testing workflows

### Providers

- **Patient Referred for Testing**

  Work with local public health officials to provide guidance on expanded access to testing and prioritization

### Sample Collection sites

- **Collection Site Collects Samples**

  Work to set up a state-wide network of new collection sites
  Secure sufficient supplies for sample collection

### Sample Processing sites

- **Network of Organizations Processing Tests**

  Optimize supply distribution for existing tests
  Identify and scale promising new tests

### Test results captured and reported

Track results and make them available in aggregate to the public.

---

**CA Task Force Team**

---

**Image Credits:**
- Covid-19 Testing Task Force
The network of testing sites is being expanded to provide equitable access across the state.

Criteria for recommendation of additional sites:

- Ensure access to testing in underserved communities
- Ensure a collection site within approx. **30 min** driving time in urban areas and within approx. **60 min** in rural areas
- Ensure there is sufficient capacity to meet state requirements for reopening (**1.5 tests per 1,000 people**)

Network of testing active sites in California:

- OptumServe sites: **78**
- Verily sites: **14**
- Other community sites (including drive-throughs, clinics, urgent care centers, and other sites): **340+**

Current as of 05/17
The Task Force has launched an integrated directory of testing sites

Locations and working hours for all Verily, OptumServe, and other community testing sites

Search by location (address, zip, county)

Links and phone numbers to schedule appointments

https://www.arcgis.com/apps/Nearby/index.html?appid=43118dc0d5d348d8ab20a81967a15401
The state is preparing to open additional testing sites in rural counties

**Testing site options for rural counties include:**

- Mobile vans
- Shared testing sites for two or more neighboring rural counties
- Pharmacies
- Home-based testing
The Task Force is working to secure scarce supplies for sample collection and test processing

Sample collection supplies

• The Task Force confirmed and operationalized supply distribution model in partnership with RDMHSs and MHOACs.
• Distribution completed for 1.2M swabs and 770k units of viral transport media.
• 2M+ swabs expected to be delivered and distributed in the next 4 weeks.
• 200+ resource requests completed since April.

Test processing supplies

• The Task Force is in active collaboration with all major manufacturers to resolve supply shortages.
• The state purchased 1.5M Abbott serology kits and 250k testing kits for Abbott m2000 machines.

Current as of 05/19
California has sufficient lab capacity to meet the Task Force’s daily testing goal

Capacity for PCR COVID-19 test processing in California

1 Relative capacity takes into account availability of supplies for test processing and lab operating hours
2 Calculation based on lab reported install base, assume same throughput as Panther Fusion once test kit is approved

SOURCE: Install base aggregates data reported by labs; information is being refined through targeted outreach

Current as of 05/19
We are tracking tests/day daily

Total testing volume in California, tests/day

- 10,000 (goal by 4/17)
- 25,000 (goal by end of April)
- 60,000 (goal by end of May)

Current as of 05/17

End of March

- Apr 4
- Apr 8
- Apr 12
- Apr 16
- Apr 20
- Apr 24
- Apr 28
- May 2
- May 6
- May 10
- May 14

We are tracking tests/day daily.

Total testing volume in California, tests/day.
We will use this information to provide recommendations as to where collected specimens should be sent.

Specimen collection by hospitals (inpatient and outpatient) → Hospital-owned labs

Drive-through centers, clinics, physician offices, urgent care centers → High-throughput labs

Specimen collection in congregate setting → Public health labs

Role of the Task Force:
- Guide people toward staffed and supplied collection sites
- Match collection sites & specimens to labs that have capacity for faster test processing turnaround
Assessment approach

<table>
<thead>
<tr>
<th><strong>Serology tests</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(details follow)</td>
</tr>
<tr>
<td>Technical assessment that includes a comprehensive set of performance metrics and follows a systematic multi-step approach</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rapid point of care tests</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Focus on symptomatic cases in ER, ICU, or congregate settings, vulnerable populations, and first responders</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Specimen pooling</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment focused on feasibility and identification of low prevalence areas where pooling may be beneficial</td>
</tr>
</tbody>
</table>
The Task Force has developed recommended minimum performance levels for serology tests

Assessment scheme

Step 1: Does the testing method have performance data derived from clinically and scientifically valid methods?

Step 2: Does the testing method have adequate clinical sensitivity (min 90%) and specificity (99%)?

Step 3: What is the relationship of sensitivity/specificity and predictive values for each test method?

Step 4: What are additional available performance metrics (e.g., turnaround time, specimen type, reagent stability and availability)?
The Task Force is monitoring new technologies that promise to increase access to testing.

Infectious Disease Society of America (IDSA) Guidelines on the Diagnosis of COVID-19:

Suggests mid-turbinate (MT) or nasal swabs are acceptable alternatives to nasopharyngeal swabs in symptomatic individuals.

Suggests that nasal and MT swabs may be collected by either patients (at home self-collection with appropriate training) or healthcare providers.

Saliva collection: Insufficient data. Given significant interest, the panel anticipates additional studies to better inform on test performance.

Tests with at home self collection kits now available: Current as of May 17, 2020
- Rutger’s Clinical Genomics Lab – Saliva
- Pixel by LabCore – Nasal swab
- Fulgent Therapeutics, LLC* – Nasal swab
- Assurance Scientific Laboratories* – Nasal swab

* Everlywell supplies COVID-19 nasal swab kit
What we hope you take away from this session

• We have developed a comprehensive but highly manual picture of testing in CA
• Picture is dynamic, changing every day
• Task Force is working hard to help:
  • Optimize distribution of testing supplies and equipment where needed
  • Recommend when new tests should be put into widespread use
  • Propose resources needed to expand testing capacity
  • Ensure equitable and appropriate statewide access to testing
• Efforts are gaining traction as we have moved from ~2,000 tests per day when we started, to going past our 25,000 tests per day goal by end of April and currently up to ~53K per day as our latest 3-day average (05/14 to 05/16)
• We have a path to further increase tests per day to 60,000-80,000 per day and plenty of work left to do to achieve it
Next Steps

• Visit testing.covid19.ca.gov to learn more

• Ongoing newsletter with updates about our work

• Please reach out to testing.taskforce@state.ca.gov if you have any questions about the Task Force efforts